Accéder au contenu
Merck

Exploring the target scope of KEAP1 E3 ligase-based PROTACs.

Cell chemical biology (2022-09-08)
Guangyan Du, Jie Jiang, Nathaniel J Henning, Nozhat Safaee, Eriko Koide, Radosław P Nowak, Katherine A Donovan, Hojong Yoon, Inchul You, Hong Yue, Nicholas A Eleuteri, Zhixiang He, Zhengnian Li, Hubert T Huang, Jianwei Che, Behnam Nabet, Tinghu Zhang, Eric S Fischer, Nathanael S Gray
RÉSUMÉ

Targeted protein degradation (TPD) uses small molecules to recruit E3 ubiquitin ligases into the proximity of proteins of interest, inducing ubiquitination-dependent degradation. A major bottleneck in the TPD field is the lack of accessible E3 ligase ligands for developing degraders. To expand the E3 ligase toolbox, we sought to convert the Kelch-like ECH-associated protein 1 (KEAP1) inhibitor KI696 into a recruitment handle for several targets. While we were able to generate KEAP1-recruiting degraders of BET family and murine focal adhesion kinase (FAK), we discovered that the target scope of KEAP1 was narrow, as targets easily degraded using a cereblon (CRBN)-recruiting degrader were refractory to KEAP1-mediated degradation. Linking the KEAP1-binding ligand to a CRBN-binding ligand resulted in a molecule that induced degradation of KEAP1 but not CRBN. In sum, we characterize tool compounds to explore KEAP1-mediated ubiquitination and delineate the challenges of exploiting new E3 ligases for generating bivalent degraders.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Cocktails d'inhibiteurs de protéases Mini cOmplete, Tablets provided in a glass vial
Sigma-Aldrich
Lenalidomide, ≥95%